HilleVax, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing novel vaccines. The company is headquartered in Boston, Massachusetts and currently employs 14 full-time employees. The company went IPO on 2022-04-29. The firm's programs, HIL-214 and HIL-216, are virus-like particle (VLP) based vaccine candidates in development for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection. HIL-214 consists of VLPs which are designed to mimic the structure of norovirus and are co-formulated with an alum adjuvant to enhance immunogenicity and stability of the VLPs in solution. HIL-214 is administered intramuscularly via prefilled syringes and has demonstrated stability at standard refrigeration temperatures of four degrees Celsius for 24 months. The firm has in-licensed HIL-216 from Chengdu Kanghua Biological Products Co., Ltd. (Kangh), a Chinese company. Its license provides world-wide rights to the vaccine outside of the Chinese market. HIL-216 includes six common norovirus genotypes: GI.1, GII.2, GII.3, GII.4, GII.6 and GII.17.
Follow-Up Questions
Who is the CEO of Hillevax Inc?
Dr. Robert Hershberg is the Chairman of the Board of Hillevax Inc, joining the firm since 2020.
What is the price performance of HLVX stock?
The current price of HLVX is $2.09, it has decreased 0% in the last trading day.
What are the primary business themes or industries for Hillevax Inc?
Hillevax Inc belongs to Biotechnology industry and the sector is Health Care
What is Hillevax Inc market cap?
Hillevax Inc's current market cap is $104.7M
Is Hillevax Inc a buy, sell, or hold?
According to wall street analysts, 4 analysts have made analyst ratings for Hillevax Inc, including 0 strong buy, 0 buy, 3 hold, 1 sell, and 0 strong sell
